FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Genetic Testing, Prevention
Study : Survival and mutation status in breast cancer patients under age 40
Most relevant for: Young breast cancer patients
Studies have found conflicting rates of survival for BRCA mutation carriers who develop breast cancer, reporting better, worse and similar outcomes compared to patients with sporadic breast cancer. New results of the large Prospective Outcomes in Sporadic versus Hereditary (POSH) breast cancer study found no difference in survival rates between the two groups. The study also concluded that among young triple-negative breast cancer patients during the first 2 years after diagnosis, BRCA mutation carriers had an initial survival advantage compared to women without a BRCA mutation. (02/15/18)
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : What is the risk of breast cancer recurrence after nipple-sparing mastectomy?
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Breast cancer patients who are considering or have had a nipple sparing mastectomy
Nipple-sparing mastectomy (NSM) offers better cosmetic results for women who have immediate breast reconstruction (at the same time as their mastectomy). Over the past decade, NSM has gained popularity among surgeons and patients. Studies show that women who keep their own nipples have higher rates of satisfaction and psychological well-being after mastectomy and reconstruction compared to women who lose their nipples. However, little data exists on the long-term risk of recurrence following NSM. New research adds to a growing body of evidence suggesting that risk of recurrence is low after NSM in carefully selected patients with breast cancer. (1/25/18)
Read More
Relevance: Medium-Low
Strength of Science: Medium-Low
Research Timeline: Human Research
Study : No new high-risk breast cancer genes here
Relevance: Medium-Low
Strength of Science: Medium-Low
Research Timeline: Human Research
Most relevant for: People with a family history of breast cancer but no known inherited mutation
While some of the genes that cause hereditary breast cancer are known (for example, inherited mutations in genes like BRCA, ATM and PALB2), others remain unidentified. Two studies found 72 DNA changes (also known as “variants” or “SNPs”) that affect breast cancer risk. These variants are different from mutations in genes that dramatically increase cancer risk. Most of these new variants are located outside of the portion of DNA that is used to make proteins. Further research is needed on these new variants before they can be used by doctors to help people understand and manage their risk for cancer. (1/12/18)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Genetic counseling by phone or face-to-face
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People referred to a genetic counselor or those considering genetic testing
Results presented at the 2017 American Psychological Association’s annual meeting showed genetic counseling by telephone is as “safe and effective” in long-term psychological and social outcomes compared to traditional in-person counseling for women at risk for hereditary breast and ovarian cancer. This presentation is an update on research published in 2014. (11/29/17)
Read More
Article : Preimplantation genetic diagnosis and hereditary cancer
Most relevant for: people with an inherited mutation linked to cancer risk
Andrew Joseph’s piece for STAT, “A baby with a disease gene or no baby at all: Genetic testing of embryos creates an ethical morass,” focuses on preimplantation genetic diagnosis (PGD) and the emerging ethical issue in the field of reproductive medicine: What to do when patients seeking to get pregnant select embryos with DNA that could lead to a disease or a disability. (11/8/17)
Read More
Study : Alcohol and breast cancer risk in African American women
Most relevant for: African American women who would like to lower their breast cancer risk
The link between alcohol intake and breast cancer is well known, but most studies have involved only White women. Recently, a large study of more than 22,000 African American (AA) women found that similar to White women, increased alcohol consumption is associated with a greater risk of breast cancer. (10/27/17)
Read More
Article : Mixed reviews of at-home genetic testing
Most relevant for: People who are considering or have had direct-to-consumer testing
National guidelines recommend that patients meet with a genetics expert before undergoing genetic testing for cancer risk. Genetic counseling can help patients decide whether genetic testing is right for them and order the most appropriate test. Once test results are available, genetics experts also help patients understand their results. Over the last decade, the popularity of direct-to-consumer (DTC) genetic testing, such as 23andMe has grown. Some genetic tests are marketed to consumers on television, in print advertisements, and on the Internet. These “at-home” genetic tests give people direct access to their genetic information without first involving a healthcare provider in the process. A recent report outlines the benefits and limitations of DTC genetic testing. (10/20/17)
Read More
Article : Can lifestyle changes impact breast cancer risk?
Most relevant for: Any woman concerned about her risk for breast cancer
A recent New York Times article shared how “adopting protective living habits” could help keep breast cancer “at bay”. While many of these lifestyle changes and strategies like not smoking, avoiding weight gain, reducing alcohol consumption, eating a heart-healthy diet, and increasing physical activity have been shown to reduce breast cancer risk, there are other risk factors that one cannot control such as having a BRCA or other mutation that significantly increases breast cancer risk. Importantly, no one strategy has been proven to totally eliminate breast cancer risk. However many of these approaches have overall health benefits. (9/21/2017)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Does expanded genetic testing benefit Jewish women diagnosed with breast cancer?
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Jewish women with breast cancer who previously tested negative for the three most common BRCA mutations
BRCA1 and BRCA2 mutations are common in people of Eastern European (Ashkenazi) Jewish descent. About 2% of all Ashkenazi Jewish people will test positive for one of three common mutations in these genes. Genetic testing for Jewish people sometimes focuses on only the three most common mutations. For Jewish women with breast cancer, little is known about their chance of carrying a different hereditary mutation that may increase risk. This study looked at expanded genetic testing in Jewish women diagnosed with breast cancer to learn how often they carried mutations other than the three most common BRCA gene mutations found in Ashkenazi Jewish people. (09/13/17)
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Study : Does aspirin lower a woman’s breast cancer risk?
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: Women at average risk for breast cancer
Women who take aspirin regularly may have a reduced risk of breast cancer. However, previous studies have reported mixed results. Few of these studies have looked at whether this potential benefit of aspirin is linked to specific types of breast cancer. This study found a small reduction in breast cancer risk for women who took a low-dose aspirin at least three times per week, but only for one subtype of breast cancer. Women who took aspirin were less likely to develop ER/PR-positive, Her2- negative breast cancer, the most common type of breast cancer. This study found no breast cancer risk reduction for women who used regular-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDS). (8/29/17)
Read More